Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.64 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17800997 | 0.86 | IDO1 (0.75) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL12647751 | 0.81 | CYP11B1 (0.70) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL27880327 | 0.80 | IDO1 (0.67) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL482297 | 0.78 | IDO1 (0.64) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL1951516 | 0.78 | IDO1 (1.00) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL872238 | 0.78 | IDO1 (0.64) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL496675 | 0.78 | IDO1 (0.64) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL872388 | 0.78 | POLB (1.00) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL14705340 | 0.78 | IDO1 (0.64) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL17782163 | 0.78 | ASIC3 (1.00) | IDO1ASIC3POLBSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-10961266-B2 | Chemoselective methylene hydroxylation in aromatic molecules | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087331-A1 | CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-03-19 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-0654030-A1 | IMIDAZOLE DERIVATIVES HAVING A II ANTAGONIST ACTIVITY. | LUSO FARMACO INST (IT) | 1995-05-24 | — | — | EP | disclosed |
| EP-0508999-A1 | PHARMACEUTICALLY ACTIVE NORMONYL COMPOUNDS | Beecham Group p.l.c. (GB) | 1992-10-21 | — | — | EP | disclosed |
| WO-1991009855-A1 | PHARMACEUTICALLY ACTIVE NORMONYL COMPOUNDS | BEECHAM GROUP PLC (GB) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | IDO1 3136/4885ASIC3 4280/4885POLB 61/4885 |
| US-10961266-B2 | Chemoselective methylene hydroxylation in aromatic molecules | PAH, DBH, AHR | IDO1 1166/4885ASIC3 1874/4885POLB 991/4885 |
| US-20200087331-A1 | CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES | PAH, DBH, AHR | IDO1 1166/4885ASIC3 1874/4885POLB 991/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885ASIC3 4691/4885POLB 2996/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | IDO1 639/4885ASIC3 4803/4885POLB 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.